Preliminary study of nanonized lamotrigine containing products for nasal powder formulation by Gieszinger, Péter et al.
© 2017 Gieszinger et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php 
and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you 
hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission 
for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
Drug Design, Development and Therapy 2017:11 2453–2466
Drug Design, Development and Therapy Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
2453
O r i g i n a l  r e s e a r c h
open access to scientific and medical research
Open access Full Text article
http://dx.doi.org/10.2147/DDDT.S138559
Preliminary study of nanonized lamotrigine 
containing products for nasal powder formulation
Péter gieszinger
ildikó csóka
edina Pallagi
gábor Katona
Orsolya Jójárt-laczkovich
Piroska szabó-révész
rita ambrus
Faculty of Pharmacy, institute of 
Pharmaceutical Technology and 
regulatory affairs, University of 
szeged, szeged, hungary
Abstract: The nasal delivery of drugs offers a great alternative route to avoid adverse events 
and to increase patient compliance due to its advantageous properties. Besides nasal applica-
tion, topical, systemic and central effects are also available. Nasal powders (NPs) have better 
adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, 
their bioavailability is better compared to the liquid formulations. Using nanoparticles, innova-
tive and more efficient products can be achieved, which may lead to the improvement of dif-
ferent therapies. The aim of this study was to produce NP formulations containing lamotrigine 
(LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk 
assessment of the preliminary tests, the micrometric properties (particle size and morphology) 
and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction 
[XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and 
in vitro dissolution and diffusion profiles were also examined. These product samples showed 
an appropriate particle size ranging 10–25 µm, while the particle size of LAM in the products 
was between 120 and 230 nm and the dissolved amount of drug was .60% after 5 minutes in 
these cases.
Keywords: nanonization, nasal powder, lamotrigine, co-milling, risk assessment
Introduction
The nasal cavity as an alternative route of drug administration became very important 
in the past years. By formulating nanoparticles for nasal application, the unpleasant 
effects can be reduced or eliminated due to the advantages of this alternative route 
and the increased specific surface area of the particles.1 Local, systemic and central 
nervous system (CNS) effects are also available through nasal application.2–4 This 
kind of drug administration could be useful in the therapy of CNS diseases;5 therefore, 
eg, carbamazepine, morphine or olanzapine was applied in the present study.6 Our 
research group investigated nasal liquid formulations previously;1,7–9 in our present 
study, this is the first time when powder formulations for intranasal application 
were investigated.
Nasal powders (NPs) are formulated to have favorable physicochemical and 
microbiological qualities and stability; thus, preservatives are not needed. They have 
high adhesion ability and rapid onset of action;10 therefore, innovative products can 
be generated by using modern applicators and formulating nanoparticles. The quality 
recommendations and quality requirements concerning NPs are included in regulations 
and guidelines about the nasal and inhalation products of the international authorization 
bodies.11–14 From a regulatory point of view, nasal products as powerful drug delivery 
systems are special because they are recommended to be planned, developed and 
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optimized parallel with the delivery device (eg, NP inhaler, 
NP sprayer, NP insufflators) in order to assure proper 
dosing.15,16 For dry powders, the related European Medicines 
Agency (EMA) and US Food and Drug Administration (FDA) 
guidelines recommend special attention and critical thinking 
about the following: 1) drug substance specifications, such 
as particle size (in related literature, it is recommended to be 
.20 µm), particle size distribution, crystalline form, shape 
and crystallinity, which could be critical for product and 
aerodynamic performance; 2) excipient specifications and 
3) sensitivity testing of humidity and temperature.11,12,17,18 
Most of the currently used active pharmaceutical ingredi-
ents (APIs) are poorly water soluble; thus, property repair 
technologies, eg, dry milling, are required considering the 
technological parameters (applied excipients and procedures) 
based on preliminary design as a part of the Quality by Design 
(QbD) method.
The additives used in powder formulations have a great 
influence on nasal absorption because residence time on 
the nasal mucosa is increased and they hold cells together; 
thus, the API can penetrate through the membranes more 
effectively. The most commonly used types of additives 
are mucoadhesive polymers, such as sodium hyaluronate 
(NaHA) and hydroxypropyl cellulose (HPC),1,10 which aim 
to increase the residence time of API on the nasal mucosa, 
which leads to improved penetration. Polyvinyl alcohol 
(PVA) and polyvinylpyrrolidone K25 (PVP_K25) are often 
used polymers to preserve the individuality of the particles 
and to open the tight junctions.19,20
Particle size reduction to the nano range is a promis-
ing way to improve the dissolution rate properties of 
poorly water-soluble drugs.21 Top–down processes such 
as co-grinding produce micro- or nanoparticles by using 
mechanical stresses. These technologies are environmentally 
and economically advantageous because they are organic 
solvent free, simple and well reproducible.22–24 In this case, 
nanoparticles are produced by grinding the drug together with 
one or two additives, which are responsible for the stability 
and maintenance of the uniqueness of the particles.25
QbD is a holistic and systematic quality management 
method,26 where the development design is risk and knowl-
edge based; thus, the experiments in practice can be planned 
more efficiently.27 In a QbD-based development, the first step 
is the prior definition of the quality target product profile 
(QTPP; essential parameters from the point of view of the 
patient and the clinical setting). The next step is the selec-
tion of the parameters that influence the QTPPs critically. 
These are the critical quality attributes (CQAs) related to 
the materials and product and the critical process parameters 
(CPPs) related to the selected production method. The key 
element of a QbD-guided development is risk assessment 
(RA), which can be initial, updated or final. Good RA results 
are essential for designing the studies in practice. The RA-
based development and screening could be more effective 
and can be used successfully even in the early development 
of pharmaceutical products.28,29
The previous studies of our research group focused on the 
nasal delivery of nanonized nonsteroidal anti-inflammatory 
drugs (NSAIDs) using QbD approach.28,29 In the present 
article, the aims of the authors were to produce and investi-
gate nanonized API containing NP compared to its interactive 
physical mixtures (PMs). The QbD method-based initial 
RA was also performed to predict the factors that have 
the highest influence on the quality of the product. During 
the study, we applied a poorly water-soluble drug called 
lamotrigine (LAM; 0.17 mg/mL in water at 25°C) as a model 
drug and PVP_K25, PVA and NaHA as additives for the NP 
formulation.30 The nose as an alternative and effective route 
of administration and the nanonized particles together could 
be beneficial in the therapy of different diseases.
Materials and methods
Materials
LAM, a second-generation antiepileptic drug of the phe-
nyltriazine class, was purchased from Teva Ltd. (Budapest, 
Hungary). PVP_K25 and PVA, both water-soluble synthetic 
polymers, were supplied by ISP Customer Service GmBH 
(Cologne, Germany). Sodium hyaluronate (NaHA) poly-
mer was purchased from Gedeon Richter Ltd. (Budapest, 
Hungary).
Methods
initial ra
To perform the QbD-based initial RA, the first step was the 
determination of the QTPP of the aimed product. After that, 
the CQAs and the CPPs of the selected production method 
were identified. To this identification, a knowledge space 
development was executed as part of the QbD methodology 
and an Ishikawa diagram was set up. For performing the RA, 
the LeanQbD® software (QbD Works LLC, Fremont, CA, 
USA) was used as a technical tool. The first step of RA was 
to carry out an interdependence rating among the QTPPs and 
CQAs and also among the CQAs and CPPs. A three-level 
scale was used to describe the relation between the param-
eters. Accordingly, the interaction between the elements 
was described as “high” (H), “medium” (M) or “low” (L). 
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Figure 1 Protocol of sample preparation.
Abbreviation: aPi, active pharmaceutical ingredient.
Table 1 applied ratios (w/w) and milling parameters for nP 
formulation
Samples Ratio Milling time 
(hours)
Milling speed 
(rpm)
r_laM_PVP_K25 1:1 2 400
r_laM_PVa
r_laM_naha
Abbreviations: nP, nasal powder; laM, lamotrigine; PVP_K25, polyvinylpyr rolidone 
K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
The dynamism of this interdependence rating is presented in 
tables generated by the software. This was followed by the 
probability rating step, in which CPPs were estimated and 
categorized on a 10-point scale. Finally, Pareto charts were 
generated by the software, presenting the numeric data and 
the ranking of the CQAs and CPPs.
Preparation of the samples
PVP_K25, PVA and NaHA were used for sample prepara-
tion as additives to maintain the stability and individuality 
of nanonized LAM particles. Figure 1 shows the process 
of sample preparation, where 1–1 g of LAM and additives 
(1:1 ratio) were placed in a Turbula mixer (Turbula System 
Schatz; Willy A. Bachofen AG Maschinenfabrik, Basel, 
Switzerland) using 60 rpm for 10 minutes; thus, interactive 
PMs were prepared.
During the preliminary experiments, the effects of three 
ratios of APIs, additive (1:1, 1:2 and 2:1), milling time (2, 
4 and 6 hours) and speed (200, 400 and 600 rpm), were 
investigated. The optimal parameters of dry milling were 
selected on the basis of these experiments and can be found 
in Table 1.
After mixing, the PM samples – which were the first 
state of sample preparation and were used for comparison 
to the co-milled products – were placed into a planetary 
ball mill (Retsch PM 100; Retsch, Neuhausen, Germany), 
where they were milled for 2 hours at 400 rpm in a 50 mL 
capacity milling chamber. For milling, 10 steel balls (diam-
eter 10 mm, weight of each ball 4.02 g) were used to get 
the co-milled samples (R).
Particle size analysis
Particle size was characterized by using Leica Image 
Processing and Analysis System device (Leica Q500MC; 
Leica Microsystems, Wetzlar, Germany). The test parameters 
of .300 particles were their length, width, area and district/
convex perimeter.
scanning electron microscopy (seM)
The morphology of the powder microparticles was inves-
tigated by SEM (Hitachi S4700; Hitachi Ltd., Tokyo, 
Japan) at 10 kV. The samples were gold–palladium coated 
(90 seconds) with a sputter coater (Bio-Rad SC502; VG 
Microtech, Uckfield, UK) using an electric potential of 
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2.0 kV at 10 mA for 10 minutes. The air pressure was 
1.3–13.0 mPa. Distributions of LAM particle diameter were 
obtained by analyzing SEM images with the ImageJ software 
environment using ~500 particles.
raman spectroscopy
In this article, dispersive Raman spectrometer was used to 
confirm the relatively uniform distribution of API. Transmis-
sion Raman spectroscopy is used for the non-invasive and 
fast, qualitative investigation of pharmaceutical dosage forms 
and powder mixtures. In our method, the distribution of LAM 
was analyzed by Raman surface mapping. To investigate 
the distribution of API, Raman spectra were acquired with 
a Thermo Fisher DXR Dispersive Raman (Thermo Fisher 
Scientific, Waltham, MA, USA) equipped with a charge-
coupled device (CCD) camera and a diode laser operating at 
a wavelength of 532 nm. Raman measurements were carried 
out with a laser power of 4 and 8 mW at a 25 µm slit aperture 
size on a 2 µm spot size. Spectra of the individual substances 
as PVA and LAM were collected using 6 second exposure 
time, a total of 48 scans in the spectral range of 1,700–
200 cm−1 with cosmic ray and fluorescence corrections.
Differential scanning calorimetry (Dsc)
The thermal response of each product was measured using 
a differential scanning calorimeter (Mettler Toledo TG 
821e DSC; Mettler Inc., Schwerzenbach, Switzerland). 
About 3–5 mg of powder was precisely weighed into DSC 
sample pans, which were hermetically sealed and lid pierced. 
Each sample was measured in the temperature interval of 
25°C–230°C at a heating rate of 5°C/min and at a rate of 
5°C/min under constant argon flow of 150 mL/min. Data 
analysis was performed using the STARe software (Mettler 
Toledo; Mettler Inc., Schwerzenbach, Switzerland).
X-ray powder diffraction (XrPD)
The XRPD measurement was carried out with a BRUKER D8 
advance X-ray powder diffractometer (Bruker AXS GmbH, 
Karlsruhe, Germany) with Cu⋅K λI radiation (λ=1.5406 Å) 
and a VÅNTEC-1 detector (Bruker AXS GmbH, Karlsruhe, 
Germany). The powder samples were loaded in contact with 
a plane quartz glass sample slide with an etched square and 
measured. Samples were scanned at 40 kV and 40 mA. The 
angular range was 3°–40° 2θ, at a step time of 0.1 seconds 
and a step size of 0.007°. All manipulations, including Kα2 
stripping, background removal and smoothing of the area 
under the peaks of the diffractograms, were performed using 
the DIFFRACplus EVA software. The crystallinity index 
(X
c
) values were calculated based on the following formula, 
where A marks the area under the whole curve:
 
X
A
A Ac
crystalline
crystalline amorphous
=
+
× 100
solubility test
The thermodynamic solubility of LAM was determined in 
distilled water at 25°C (pH 5.5) and in phosphate buffer 
(pH 5.6) at 30°C presented the conditions of the nasal 
mucosa. In all, 10 mg of LAM or LAM-containing sample 
in 5 mL distilled water or phosphate buffer was stirred with 
a magnetic stirrer for 6 hours. After 2 hours, they were fil-
trated (0.22 mm, FilterBio PES Syringe Filter; Labex Ltd., 
Budapest, Hungary) and the content of the dissolved drug 
was measured spectrophotometrically at 362 and 267 nm in 
the case of water and pH 5.6 buffer, respectively (Unicam 
UV/Vis Spectrophotometer; Unicam, Cambridge, UK).
surface free energy and polarity investigation
To determine the contact angle, surface free energy and 
polarity, 0.15 g of sample on 1 ton hydraulic press (PerkinElmer 
Hydraulic Press; PerkinElmer Inc., Waltham, MA, USA) was 
forcibly pressed to pastille. Then, the surface of the pastilles 
was dripped with polar and non-polar solvents. The contact 
angle was detected for 30 seconds with DataPhysics OCA 20 
device (DataPhysics Inc. GmbH, Filderstadt, Germany), and 
then, Wu correlation was used. The solvents were distilled 
water (γ p=50.2 mN/m, γ d=22.6 mN/m) and diiodomethane 
(γ p=1.8 mN/m, γ d=49 mN/m).
Dissolution test
The modified paddle method (USP dissolution apparatus, 
type II; Pharma Test, Hainburg, Germany) was used to 
examine the rates of dissolution of poorly water-soluble 
LAM-containing samples and determine the drug release 
profile from the samples. The test was carried out under nasal 
conditions; thus, the medium was 100 mL phosphate buffer 
(PBS of pH 5.60 at 30°C), in which 120 mg of the samples 
were put. The paddle was rotated at 50 rpm, and the sampling 
was performed up to 60 minutes. After filtration, the drug 
contents of the aliquots were determined using spectropho-
tometry (Unicam UV/VIS Spectrophotometer) at 364 nm.
Statistical analysis of LAM dissolution profile
The percentage dissolution efficiency (%DE) for each 
sample was calculated as the percentage ratio of the area 
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under the dissolution curve up to time t to that of the area 
of the rectangle described by 100% dissolution at the same 
time as follows:
 
% %DE =
×
×
×0
100
100
t
y dt
y t
∫
The relative dissolution (RD) time at 30 minutes (RD
30 min
) 
in the case of co-milled samples was calculated using the 
formula:
 
RD
DE R
DE PM
min
% min
% min
30
30
30
=
A well-known method is the trapezoidal method. The 
area under the curve (AUC) is the sum of all the trapezia 
defined by:
 
AUC
n
=
− +
=
− −∑ ( )( )
i
i
i
t t y y
1
1 1 1
2
=
i i
 
where t
i
 is the time point and y
i
 is the percentage of product 
dissolved at time t
i
. The mean dissolution time (MDT) was 
calculated via the following expression:
 
MDT
n
mid
n
= −
−
∑
∑
i
i
M
M
1
1
t ∆
∆
where i is the dissolution sample number, n is the number 
of dissolution times, t
mid
 is the time at the midpoint between 
times t
i
 and t
i−1
 and ∆M is the amount of LAM dissolved (mg) 
between times t
i
 and t
i−1
.
side-Bi-side™ horizontal diffusion studies
The Side-Bi-Side™ (Crown Glass, USA) diffusion test was 
carried out in nasal conditions. The cellulose ester mem-
brane with 0.45 µm pore diameter was soaked in isopropyl 
myristate, and the donor phase was tempered to 30°C at 
pH 5.6. The acceptor phase was pH 7.4, and the content of 
the diffused drug was measured spectrophotometrically at 
362 nm (Unicam UV/Vis Spectrophotometer).
Results and discussion
Knowledge space development and ra
The first step was setting up an Ishikawa (fishbone) diagram 
including all the parameters influencing the desired NP 
product containing LAM as the active agent. The param-
eters were ranked into four groups (Figure 2), namely, 
1) material characteristics; 2) production method; 3) product 
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Figure 2 Ishikawa diagram illustrating the parameters influencing the quality of the nanonized LAM containing NP product.
Abbreviations: laM, lamotrigine; nP, nasal powder; aPi, active pharmaceutical ingredient; PVP_K25, polyvinylpyrrolidone K25; naha, sodium hyaluronate; seM, scanning 
electron microscopy; Dsc, differential scanning calorimetry; XrPD, X-ray powder diffraction; gi, gastrointestinal; cns, central nervous system.
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characteristics and 4) therapeutical expectations. This process 
gave a collection of preliminary knowledge and information, 
which helped to design the experiments and to select the appro-
priate CQAs and CPPs of the drug development procedure.
First of all, the QTPPs that describe the desired NP-
containing nanosized LAM were defined, and the CQAs and 
the CPPs were also identified. The results of interdependence 
rating made by the research group members and the selected 
target and critical parameters are presented in the tables 
of Figure 3. Below them, Pareto charts can be seen, as the 
result of the RA generated by the software. The Pareto charts 
show the relative effect of the CQAs and the CPPs on the 
QTPPs, namely, the numeric data of the critical factors and 
their ranking. In the diagrams, the same colors were used as 
in the tables; the factors that have the minimal effect on the 
final product quality were marked with green, the factors 
with the medium effect were marked with yellow and the 
factors with great impact were marked with red. As a result, 
it was found that theoretically among the CQAs, the particle 
size and its distribution can be predicted to have the greatest 
effect on the quality of the targeted and desired NP product. 
The analog diagram shows that among the CPPs, milling time 
and speed had to be expected to have the highest influence 
on the quality of the aimed product (Figure 3). According 
to the RA results, the studies of the practical development 
(screening studies and product preparation) were focused on 
the selected CQAs (particle size and distribution of LAM and 
dissolution, as investigated outputs) and CPPs (milling time, 
milling speed and the API:additive ratio).
According to the results of the initial RA, the ratio of API 
and additives was found to be critical. In this meaning, in 
all additives, a ratio of 1:1 was selected for production; the 
milling time and milling speed were also constant (Table 1), 
and the LAM size in the product, distribution and dissolution 
as responses were investigated afterward.
effect of milling on the properties of the 
raw materials
Preliminary experiments were carried out to collect informa-
tion about the impact of grinding on raw materials (LAM 
and excipients), and they were required because adhesion, 
aggregation and amorphization may occur due to grinding.
Micrometric properties (particle size and 
morphology)
After 2 hours of milling, the particle size of LAM increased 
(from 8.28 to 14.26 µm) because of the aggregation of the 
particles caused by the adhesion forces. The particle size of 
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Figure 3 results of the interdependence ratings of the QTPP and cQa and of the cPP (upper parts) and the Pareto charts of the cQa and cPP with calculated numeric 
severity scores (lower parts) generated by the ra software.
Abbreviations: QTPP, quality target product profile; CQA, critical quality attribute; CPP, critical process parameter; RA, risk assessment; API, active pharmaceutical 
ingredient; l, low; M, medium; h, high.
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NaHA (from 8.96 to 26 µm) also increased after milling; 
its sponge-like structure and surface became smooth. How-
ever, the PVA (from 124.97 to 49.96 µm) and PVP_K25 
(from 21.26 to 13.06 µm) particles became smaller. This 
particle size reduction is associated with the cataract and 
cascade effects that occur during milling. The temperature 
rise during milling is not remarkable because the measured 
temperatures (25°C–37°C) do not reach the glass transition 
temperatures of the polymers. The morphology of initial 
LAM crystals was large, mainly columned, and they had 
a rough surface compared to the ground LAM, because 
those particles were nearly spherical and aggregated, which 
are factors responsible for the particle size increasing. The 
surface of the additives remained uneven after milling – 
except for PVP_K25 (because its surface in the beginning 
was nearly spherical) – but as their particle size decreased, 
due to the higher specific and uneven surface, they could 
offer an optimal polymer matrix, where the individual LAM 
particles can adhere.
structural investigations (Dsc and XrPD)
The initial materials were measured for DSC. The structure 
of LAM did not change significantly after 2 hours of milling 
because the melting point remained between 216°C and 
217°C, and the crystallinity based on normalized integral 
(−136.62 Jg−1 in the case of raw LAM and −135.09 Jg−1 in 
the case of milled LAM) did not show any changes. Based 
on the thermoanalytical results, it can be said that most likely 
decomposition or any changes in the crystal structure did not 
happen due to grinding.
XRPD investigation was carried out to confirm the results 
of DSC measurements. The diffractogram of LAM shows 
many characteristic peaks detected at 12.57, 27.04, 27.19 
and 28.92 2θ°. The intensity and location of these peaks 
did not change after milling, so the material maintained its 
crystallinity. The same can be said for the additives because 
the PVA retained its semi-crystalline nature after milling and 
PVA_K25 and NaHA also kept their amorphous property.
investigation of nP formulations
Micrometric properties
Particle size analysis
The particle size of PM samples was much higher than that of 
the co-milled samples, and they were out of the desired range 
of NPs. Nevertheless, the particle size of the co-milled samples 
(Table 2) was 10–25 µm, which is in the desired range. The 
particles are small enough to reach the nasal mucosa but not 
too small to be inhaled into the lungs. The smallest particle 
size was measured for the powder containing PVP_K25 and 
the largest one for the sample that contained PVA, particle 
size of which hardly decreased. In the table, it is also seen 
that the particle size of LAM was between 120 and 230 nm; 
it is in the target range. Compared to PM samples, it can be 
observed that in all three cases, the polymers could prevent 
the adhesion of the LAM particles, while the particle size of 
the polymers and LAM decreased due to co-milling, mostly 
in the samples that contained NaHA.
Particle size and morphology (seM)
Figure 4 shows the SEM pictures of the samples. It can 
be seen that LAM particles aggregated in the case of PM 
samples, which explains the large particle size. On the 
other hand, LAM particles adhered to the surface of the 
polymers and their size was in the nanorange. In the case of 
the PVA-containing sample, uniformly dispersed, individual 
LAM particles can be observed as well. The increase in the 
temperature level due to grinding (30°C–36°C) was not even 
in this case high enough to reach the glass transition tem-
perature of the polymers (PVP_K25: 130°C, PVA: −30°C, 
NaHA: 244°C); hence, as a result, no relevant change 
occurred. It can be concluded that the applied polymers offer 
great matrix to the LAM particles, where their individuality 
and stability, which have great influence on the dissolution, 
are ensured.
raman spectroscopy
In the PM, the distribution of PVA particles is heterogeneous. 
Polymer particles can be seen as the red area in Figure 5A, 
and in the blue area their presence is ,10%. In the ground 
sample, the presence of PVA is completely homogeneous (in 
the blue area, it is .90%; Figure 5C). It can be concluded 
that in the PM, the distribution of LAM is homogenous; 
it is presumable that LAM adhered to the PVA particles dur-
ing physical mixing (Figure 5B). In the ground sample, the 
presence of API is almost homogeneous (relatively .50% 
and ,80%; Figure 5D).
Table 2 Particle size of PM and co-milled samples
Samples Length (µm) Width (µm) Average 
particle size 
of LAM (µm)
PM_laM_PVP_K25 26.80±7.73 18.96±5.29 7.63±20.07
r_laM_PVP_K25 13.60±3.32 9.06±2.19 0.121±0.027
PM_laM_PVa 26.90±6.91 17.05±4.58 13.88±21.15
r_laM_PVa 25.33±3.47 16.61±6.35 0.15±0.042
PM_laM_naha 37.07±14.29 18.75±5.26 26.17±27.68
r_laM_naha 16.83±5.37 11.30±3.47 0.23±0.016
Abbreviations: PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrroli-
done K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
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structural investigations
Dsc
Figure 6 depicts the DSC curves of the PMs and the co-milled 
samples. On the curve of the sample containing LAM and 
PVP_K25, no endothermic peak can be detected because the 
particles merged into the polymer particles. This is what we 
experienced in our previous studies. In the case of the product 
containing NaHA, the melting point was not significantly 
different from the one in the case of the PM, but the sample 
that contained PVA showed a significant decrease in melting 
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Figure 4 Particle morphology of co-milled samples (using magnification of 1,000×-top; magnification of 15,000×-bottom).
Abbreviations: PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
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Figure 5 Raman map of the samples: PM profile to PVA (A), PM profile to LAM (B), R sample profile to PVA (C) and R sample profile to LAM (D).
Abbreviations: PM, physical mixture; PVa, polyvinyl alcohol; laM, lamotrigine.
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point. Based on the crystallinity index values (Table 3), it 
can be concluded that the crystallinity of LAM significantly 
decreased after adding PVA and NaHA.
XrPD
The intensity of the peaks decreased in each co-milled 
sample, which indicates a reduced degree of crystallinity. 
In the product containing PVP_K25, the nearly amorphous 
polymer covers the crystalline LAM; thus, the characteristic 
2θ values are not visible on the chart compared to the PM. 
A similar process took place in the sample containing PVA 
because the PM shows characteristic peaks, but the intensity 
of these peaks decreases after milling. When the sample 
contained NaHA, the amorphous property of the polymer 
is more dominant; therefore, the characteristic peaks of the 
active substance are present; however, their intensity is not 
so high as in the case of the PM (Figure 7).
The crystallinity index values were calculated after the 
investigation of the DSC curves and the XRPD diffractograms 
to reveal changes in the degree of crystallinity in the milled 
samples compared to the PMs (Table 3). It can be seen that 
the values are correlating, as similar results were obtained 
in both cases when the samples contained PVA or NaHA. 
In the case of the samples that contained PVP, the polymer 
coated the LAM crystals and at the same time protected them 
from amorphization. That is why no peak can be seen in the 
DSC curve, but the crystallinity index increased based on the 
XRPD diffractograms. The investigations were important to 
identify the crystallinity of the samples because a decrease 
in the degree of crystallinity usually leads to an increase 
in solubility.
Physicochemical analyses
solubility test
The solubility test (Table 4) shows that the solubility values are 
higher in the case of co-milled samples compared to the PM 
samples and raw LAM, regardless of whether the solvent was 
distilled water or pH 5.4 buffer. The samples that contained 
NaHA showed the best solubility in both media and the lowest 
when the additive was PVA; however, the PVA containing 
samples showed the highest improvement in the case of water 
due to the additive and the effect of milling. Compared to the 
pH 5.4 buffer, the increase in solubility of water was much 
higher, the explanation of which is that the weakly basic 
API’s solubility is higher in the weakly acidic environment. 
The results can be explained by the particle size decrease and 
the maintained individuality of the particles because of the 
effect of additives. These solubility results could predict the 
higher dissolution rate of LAM from the co-milled samples.
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Figure 6 Dsc curves of co-milled and PM samples.
Abbreviations: Dsc, differential scanning calorimetry; PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium 
hyaluronate; r, co-milled samples.
Table 3 calculated crystallinity indexes (Xc) of co-milled samples 
after Dsc and XrPD measurements compared to PM samples
Samples Xc (%)
DSC XRPD
r_laM_PVa 72.45 67.42
r_laM_PVP_K25 – 70.84
r_laM_naha 50.06 46.76
Note: ‘–’ indicates the effect of heat in PVP_K25 became amorphous and no peak 
can be detected, so crystallinity index can not be determined.
Abbreviations: Dsc, differential scanning calorimetry; XrPD, X-ray powder 
diffraction; PM, physical mixture; laM, lamotrigine; PVa, polyvinyl alcohol; 
PVP_K25, polyvinylpyrrolidone K25; naha, sodium hyaluronate; r, co-milled samples.
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surface free energy and polarity investigation
The hydrophilic and lipophilic properties of the samples 
were investigated with contact angle and polarization char-
acterization, which have great importance in passing through 
membranes for drugs. After milling, hydrophilicity improved 
because the co-milled samples wetted with water better and 
less with diiodomethane than the PMs.
The sample containing NaHA showed the most increased 
hydrophilicity, while the PM sample that contained PVA 
was unmeasurable because the mixture absorbed the drop 
instantaneously. The polarity of the PVP_K25-containing 
sample did not change appreciably. The contact angles of 
the milled samples decreased while using water compared 
to the PMs, so the polarity and the wetting ability of the 
samples increased. This means that the more polar the 
sample, the more it wets with water, which can increase 
the absorption of the product. The results shown in Table 5 
correlate with the results of the solubility test mentioned 
earlier, because higher polarity presumes higher solubility 
in water.
in vitro characteristics
Dissolution test
The in vitro dissolution test shows (Figure 8) that the dis-
solution of the co-milled samples is higher than that of the 
PMs because the dissolved amount of LAM increased in 
all cases. The dissolution rate increased the most where the 
sample contained PVA and LAM. In the co-milled sample, 
the percentage of dissolved LAM was 100% after 5 minutes. 
This means that the dissolution was the fastest for this 
sample, which can lead to a rapid onset of action. However, 
it can be said generally that dissolution rate improved due 
to the additives and the increased particle surface as a result 
of particle size reduction, because the samples containing 
NaHA and PVP_K25 also showed a significantly increased 
dissolution rate compared to PM samples.
It can be seen in Table 6 that the dissolution efficiency at 
30 minutes (DE
30 min
) was enhanced due to milling, and the 
same increase could be observed in the case of RD values. 
Similarly, the MDT values decreased, which means that 
the dissolution became faster due to the additives, particle 
size reduction and maintained individuality.
side-Bi-side™ horizontal diffusion studies
The horizontal diffusion test was carried out to investigate 
the in vitro permeability of the samples (Figure 9). It can be 
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Figure 7 XrPD diffractograms of the products.
Abbreviations: XrPD, X-ray powder diffraction; PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium 
hyaluronate; r, co-milled samples.
Table 4 solubility (mg/ml) of initial laM and co-milled samples 
in distilled water at 25°c and ph 5.4 buffer at 30°c
Sample Water (mg/mL) pH 5.4 (mg/mL)
laM 0.0996±0.0012 0.2380±0.0621
PM_laM_PVP_K25 0.0024±0.0026 0.4737±0.0484
r_laM_PVP_K25 0.2848±0.0061 0.6526±0.0157
PM_laM_PVa 0.0010±0.0007 0.2800±0.0243
r_laM_PVa 0.1515±0.0152 0.4158±0.0319
PM_laM_naha 0.0267±0.0202 0.5742±0.0425
r_laM_naha 0.1059±0.0320 0.8526±0.0212
Abbreviations: laM, lamotrigine; PM, physical mixture; PVP_K25, polyvi-
nylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled 
samples.
Drug Design, Development and Therapy 2017:11 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
2463
Development of a nasal powder formulation using preliminary design
Table 5 contact angle, surface free energy and polarity of PM and co-milled products
Samples Θ water (°) Θ diiodomethane (°) γ (mN⋅m−1) Polarity (%)
PM_laM_PVP_K25 26.08 8.2 77.18 41.16
r_laM_PVP_K25 24.2 14.35 77.17 42.45
PM_laM_PVa – – – –
r_laM_PVa 34.15 9.36 73.81 38.62
PM_laM_naha 63.05 8.45 60.37 24.22
r_laM_naha 49.36 16.06 65.81 32.80
Note: ‘–’ indicates PM sample that contained PVa was unmeasurable because the mixture absorbed the drop instantaneously.
Abbreviations: PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
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Figure 8 Dissolution curves of samples. 
Abbreviations: PM, physical mixture; laM, lamotrigine; PVP_K25, polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
concluded that the concentration of LAM was much lower 
in the acceptor phase in PMs than in the co-milled samples. 
At the end of the test, there was no significant difference 
between the PVP_K25- and NaHA-containing samples, but 
the highest LAM concentration per square centimeter after 
60 minutes was detected from the sample that contained 
PVA. It can be seen that the results correlate with the results 
of the dissolution test because the fastest dissolution and the 
highest amount of LAM release occurred from the PVA-
containing sample.
Table 7 shows the calculated flux and permeability 
coefficient values. It can be seen that the values of PMs are 
lower than the values of the co-milled samples. The sample 
containing PVA had the best permeability, whereupon 
100% of active substance passes through the membrane 
to the acceptor phase after 60 minutes. The reason of 
this high permeability can be explained by the function of 
PVA – which can preserve the uniqueness of the particles – 
and the liberation of nanoparticles. The liberation increases 
the diffusion pressure due to the increased concentration 
gradient. In the case of PVA-K25 and NaHA, there was no 
significant difference.
Conclusion
In this study, nanonized antiepileptic drug-containing pow-
ders were prepared for investigation and nasal administration 
by the co-grinding technology. This method is important 
when interactive PMs do not comply with the requirements 
of NPs.
An initial RA was performed in order to identify the 
factors that affect the quality of the desired NP product. The 
results of the RA showed that among the CQAs, particle size 
has theoretically the highest effect on the final product and 
it is influenced the most by milling time, milling speed and 
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LAM:additive ratio among the CPPs. According to the RA, 
knowledge from the literature and previous experimental 
findings, 2 hours milling at 400 rpm and 1:1 LAM:additive 
ratio were chosen as optimal parameters for the production 
process.
Co-milling was chosen as the production method to 
prepare the powder formulations because it is a simple, 
cheap, well-reproducible, environmental and economical 
method to decrease the particle size of active ingredients. 
The results showed that the changes due to milling, such 
as the decreased particle size attributed to growth surface 
and decreased crystallinity, caused better physicochemical 
properties and in vitro drug release in co-milled samples 
compared to the PM samples. By combining the advantages 
of nasal route and powder form, as well as by selecting the 
appropriate NP inhalator, the therapeutical expectations of 
different systemic and CNS diseases can be available in 
the future.
The particle size of LAM was the smallest in the sample 
that contained PVP_K25, and its solubility in water was 
the best; however, the PVA-containing powder had the 
most promising dissolution and permeability rate due to the 
outstanding uniformity of LAM particles on the surface of 
the polymer. This study confirmed that nanoparticles can 
be produced by using co-milling and applying additives, 
and these powders can be promising starting points to a 
late development, which may improve the efficiency of the 
therapy of epilepsy.
Table 6 %De, rD and MDT values of raw laM and co-milled samples
Samples %DE10 min %DE30 min %DE60 min RD30 min MDT
PM_laM_PVP_K25 25.57 38.65 44.01 1.00 8.22
r_laM_PVP_K25 22.46 39.93 54.81 1.03 19.57
PM_laM_PVa 5.97 16.09 25.29 1.00 22.02
r_laM_PVa 75.00 91.69 95.83 5.70 2.50
PM_laM_naha 2.66 6.69 16.02 1.00 35.25
r_laM_naha 11.19 36.14 54.19 5.40 20.14
Abbreviations: %DE, percentage dissolution efficiency; RD, relative dissolution; MDT, mean dissolution time; LAM, lamotrigine; PM, physical mixture; PVP_K25, 
polyvinylpyrrolidone K25; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
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Figure 9 Permeability profiles of the samples measured by Side-Bi-Side cells.
Abbreviations: PM, physical mixture; PVP_K25, polyvinylpyrrolidone K25; laM, lamotrigine; PVa, polyvinyl alcohol; naha, sodium hyaluronate; r, co-milled samples.
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